Pharmacokinetics and Preliminary Pharmacodynamics of Single- and Multiple-dose Lyophilized Recombinant Glucagon-like Peptide-1 Receptor Agonist (rE-4) in Chinese Patients with Type 2 Diabetes Mellitus

被引：0
作者：
Yitong Wang
Bingfeng Xu
Lixia Zhu
Kun Lou
Yingli Chen
Xia Zhao
Qian Wang
Ling Xu
Xiaohui Guo
Linong Ji
Yimin Cui
Yi Fang
机构：
[1] Peking University People’s Hospital,Department of Pharmacy
[2] Peking University,Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical
[3] Xuzhou Medical College,Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy
[4] Anhui Fuyang Pharmaceutical Group Co.,Clinical Medicine Department
[5] Ltd.,Department of Endocrinology
[6] CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co.,Department of Pharmacy
[7] Ltd,Department of Endocrinology
[8] Peking University People’s Hospital,undefined
[9] Peking University First Hospital,undefined
[10] Shanghai University of Chinese Medicine,undefined
[11] Peking University First Hospital,undefined
来源：
Clinical Drug Investigation | 2017年 / 37卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1107 / 1115
页数：8
相关论文
共 50 条
[21]   Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? [J].
Juris J Meier ;
Michael A Nauck .
Nature Clinical Practice Endocrinology & Metabolism, 2008, 4 :606-607
[22]   Is secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus? [J].
Meier, Juris J. ;
Nauck, Michael A. .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2008, 4 (11) :606-607
[23]   Advantages of glucagon-like peptide-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus: A review [J].
Demidova, Tatiana Yu. ;
Titova, Victoria V. ;
Izmaylova, Maryam Ya. .
TERAPEVTICHESKII ARKHIV, 2023, 95 (10) :876-880
[24]   The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes [J].
Moon, Ho-Sang ;
Kim, Mi-Kyung ;
Son, Moon-Ho .
ARCHIVES OF PHARMACAL RESEARCH, 2011, 34 (07) :1041-1043
[25]   The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes [J].
Ho-Sang Moon ;
Mi-Kyung Kim ;
Moon-Ho Son .
Archives of Pharmacal Research, 2011, 34 :1041-1043
[26]   Pharmacokinetics, safety, and tolerability of single- and multiple-dose exenatide once weekly in Chinese patients with type 2 diabetes mellitus [J].
Cui, Yi Min ;
Guo, Xiao Hui ;
Zhang, Dong Mei ;
Tham, Lai San ;
Tang, Cheng Cai ;
Mace, Kenneth ;
Linnebjerg, Helle .
JOURNAL OF DIABETES, 2013, 5 (02) :127-135
[27]   Renal Function Improvement With Glucagon-Like Peptide-1 Receptor Agonist in a Patient With Type 2 Diabetes [J].
Yanai, Hidekatsu .
JOURNAL OF MEDICAL CASES, 2024, 15 (2-3) :37-42
[28]   A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus [J].
Thondam, S. K. ;
Cuthbertson, D. J. ;
Aditya, B. S. ;
MacFarlane, I. A. ;
Wilding, J. P. ;
Daousi, C. .
CLINICAL ENDOCRINOLOGY, 2012, 77 (04) :635-637
[29]   PERIPHERAL AND CENTRAL EFFECTS OF A SINGLE DOSE OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE [J].
Wasse, L. ;
Little, T. ;
Coulson, T. ;
Bryant, C. ;
Mckie, S. ;
McLaughlin, J. .
GUT, 2014, 63 :A201-A201
[30]   Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes [J].
Ng, Elisabeth ;
Shaw, Jonathan E. ;
Wood, Anna ;
Maple-Brown, Louise J. ;
Hare, Matthew J. L. .
AUSTRALIAN JOURNAL OF GENERAL PRACTICE, 2022, 51 (07) :513-518
12345